Quick Facts: Key Uses

• Intended for the management of acute migraine attacks.
• Used to address migraine with or without aura in adults.
• May help alleviate associated symptoms like nausea and sensitivity to light and sound.

---

Нарамиг (naratriptan) is an approved medication used for the acute treatment of migraine attacks in adults. It is intended for use after a clear diagnosis of migraine has been established by a healthcare professional. This treatment option can be used to address migraine headaches that occur with or without an aura.

Its main purpose is to support the resolution of headache pain once an attack has started. The treatment may also help to relieve the associated symptoms that can accompany a migraine, such as a strong reaction to sound (phonophobia), sensitivity to light (photophobia), and nausea. Нарамиг is not indicated for the prevention of migraine attacks or for the treatment of certain other types of headaches. It is not an ordinary pain reliever.

Eligibility Scope

The regulatory profile for Нарамиг (Naratriptan) is defined by strict rules regarding age, cardiovascular health, and organ function.

Classification	Population	Status Defined by Regulators
Indicated Use	Adults (18 to 65 years)	Allowed
Not Recommended	Children (<18 years), Older Adults (>65 years)	Use Not Established/Limited Data

Contraindications (Must Not Use):

Use is contraindicated in patients with a history or current signs of ischemic heart disease (e.g., angina, history of MI, Prinzmetal’s angina), uncontrolled hypertension, or cerebrovascular syndromes (e.g., stroke or TIA). The drug is also prohibited in patients with severe renal impairment (creatinine clearance <15 mL/min) and severe hepatic impairment (Child-Pugh Grade C). Use is also contraindicated within 24 hours of taking another triptan or an ergotamine-containing drug.

Condition-Specific Restrictions:

Patients with mild to moderate renal or hepatic impairment face a regulatory restriction that limits the maximum daily dosage. Patients with multiple cardiovascular risk factors must undergo a prior cardiovascular evaluation before use.

Interactions with other medicines and products

Official regulatory documents define specific, non-advisory constraints for the co-administration of Naratriptan, centering on pharmacodynamic risks and altered drug exposure.

Vasoactive Constraints and Timing Rules

Co-administration is formally contraindicated with other potent vasoactive agents, specifically Ergotamine-containing preparations (e.g., dihydroergotamine, methysergide) and any other 5-HT1 receptor agonist (other triptans). This prohibition is due to the potential for additive vasospastic effects.

• Timing Rule: A period of at least 24 hours must elapse between the administration of Naratriptan and any of the aforementioned contraindicated agents.

Serotonergic and Herbal Interactions

A distinct pharmacodynamic interaction is documented with serotonergic medicines, including Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs). Concomitant use has been associated with reports of Serotonin Syndrome. Undesirable effects may also be more common with co-administration of herbal preparations containing St John’s Wort.

Pharmacokinetic Clearance Notes

Naratriptan's total clearance is officially documented to be altered by specific substances:

• Oral Contraceptives reduce total clearance by 32%, resulting in slightly higher plasma concentrations.
• Smoking increases total clearance by 30%.

Naratriptan does not significantly inhibit Cytochrome P450 (P450) or Monoamine Oxidase (MAO) enzymes, making metabolic interactions with drugs metabolized by these systems unlikely. Co-administration with alcohol, fluoxetine, or beta-blockers was found not to substantially modify Naratriptan's pharmacokinetics.

Population-Specific Constraints

The total clearance of Naratriptan is significantly reduced in certain populations. Clearance is reduced by 50% in moderate renal impairment and by 30% in moderate hepatic impairment, leading to increased drug exposure and specific use restrictions.

Selective Dual Agonism of Serotonin Receptors

The active ingredient, Naratriptan, acts as a selective agonist (activator) of the Serotonin 5- HT1 B and 5- HT1 D receptors. These receptors form the core biological targets for the drug. By engaging these specific receptors, the molecule initiates two distinct, yet complementary, physiological changes: the selective constriction of cranial blood vessels and the suppression of signaling from the trigeminal nerves.

---

Interrupting the Neurogenic and Vascular Cascade

The mechanism directly intervenes in the abnormal signaling of the trigeminovascular system. Activation of 5- HT1 B receptors on the blood vessel walls leads to vasoconstriction, which counteracts pathological dilation. Simultaneously, activation of 5- HT1 D receptors on the nerve endings suppresses the release of vasoactive peptides such as CGRP. This dual action modifies the early molecular steps of the pain cascade, leading to the modulation of activity within the affected vascular and neural pathways.

---

Acute, Targeted Pathway Modulation

The drug's mechanism is characterized by its role as an acute modulator, designed to rapidly interrupt the pathological state after it has commenced. This targeted receptor engagement is relevant for situations requiring short-term modulation of pathway activity to interrupt the pathological physiological responses. The mechanism is focused on acutely reversing the pathological state, a function distinct from the long-term continuous modulation required for prophylaxis.

How to Use Нарамиг

This section outlines the general principles and administration constraints for Naratriptan (Нарамиг).

---

Administration and Dosage Patterns

The medicine is designed for oral administration, utilizing a film-coated tablet in available strengths of 1 mg and 2.5 mg. It is designated strictly for acute, as-needed treatment of migraine attacks and is not indicated for preventative use. The standard starting dose for acute treatment is 1 mg or 2.5 mg. The tablet may be taken with or without food and must be swallowed whole with liquid.

Dosing Frequency and Limits

Naratriptan is used only after the onset of a diagnosed migraine headache. If a migraine returns or a partial response is achieved, a second dose may be taken, provided a minimum of four hours has passed since the first dose. The total dose must not exceed 5 mg within any 24-hour period. Furthermore, the safety of treating an average of four or more migraine attacks per month has not been established.

---

Population-Specific Constraints

Standard parameters define lower maximum daily doses for certain populations:

Population	Maximum Total 24-Hour Dose
Mild to Moderate Renal Impairment	2.5 mg
Mild to Moderate Hepatic Impairment	2.5 mg

Use in patients under 18 years of age is not established, and it is generally not recommended for patients over 65 years old. The medicine is not intended for the management of other types of headaches.

Research Evidence / Overview of Studies for Нарамиг (Naratriptan)

---

Evidence for the Acute Treatment of Migraine Attacks

The primary evidence base for Naratriptan is primarily derived from randomized controlled trials (RCTs) and systematic reviews that synthesized the RCT data. These structured studies were applied in research exploring how symptoms change over time for acute migraine episodes in adults. Researchers examined how patients responded when receiving Naratriptan compared to receiving an inactive pill (placebo). This research focuses on conditions characterized by fluctuating or episodic manifestations, specifically the acute headache phase of a migraine. The foundational evidence for the approved adult population is broadly categorized as High Level based on the consistent methodology of these trials.

How Researchers Measure Migraine Relief in Studies

In these studies, researchers monitored several key outcomes related to physical discomfort and the resolution of the acute episode. The main goals were to monitor the proportion of participants who reported a reduction in headache pain and the time intervals at which that change was reported. Outcomes describing episodic or acute changes were typically measured at fixed time intervals, most commonly two hours and four hours post-dose. Pain-free status (complete absence of pain) was also a critical measurement. Studies reported patterns of differences in pain reduction endpoints when comparing the treatment groups to the placebo groups within these specific trial settings. The measured rates for achieving the pain-free status endpoint at two hours were described as being comparatively lower than those observed for certain other study drugs.

---

Long-Term Studies and Follow-Up Data

Most of the available evidence is concentrated on the short-term treatment of a single, acute migraine attack. Primary efficacy outcomes are tracked within the first 2 to 4 hours, and sustained response is monitored up to 24 hours post-dose. Research provides insight into short-term changes, but the evidence for long-term consistency remains limited. Follow-up durations were limited for evaluating the consistency of response over many months or years of repeated use, meaning long-term outcomes are not fully established.

---

Evidence in Specific Patient Populations

Adolescents (Ages 12–17): Specific research examined use in adolescents diagnosed with migraine. However, the available data for this age group are still emerging. Regulators have noted that consistent measurement patterns in the key study endpoints were not established in this younger population when compared to placebo.

Specific Subgroups: Studies explored use in specific clinical situations, such as menstruation-associated migraine (MAM). However, there is limited information for patients with certain co-existing health conditions (comorbidities) or for older adults (over 65 years), as these groups were often excluded from the core trials.

Key Studies & References

1. Migraine Treatment and Relief (Triptans) - Patient.info (Reflecting clinical practice guidelines)

Common questions about Нарамиг (FAQ)

Q: Why can't I take this medicine during the migraine aura phase?

A: Regulatory instructions note that even when warning signals of a coming migraine, such as an aura, are present, use is intended only after the actual headache pain starts. This medicine is designed for the acute treatment of the headache phase itself.

Q: Does Нарамиг help with other migraine symptoms like light sensitivity or nausea?

A: Official product information indicates the drug is approved for the acute treatment of migraine headaches, which may include associated symptoms. However, it is also noted in regulatory documents that nausea and vomiting are themselves commonly reported adverse reactions.

Q: Does taking Нарамиг mean my headaches are definitely migraines and not something else?

A: No. Official regulatory information states that this medicine should only be used in patients who have already received a clear diagnosis of migraine. Regulatory documents state that other potential serious neurological disorders should be ruled out prior to the use of this medicine.

Q: How long does it typically take for Нарамиг to start working, and how does this compare to other triptans?

A: Clinical studies suggest that relief may begin within one to three hours, with maximum benefit potentially taking up to four hours. The drug is described as having a longer duration of action compared to some other treatments in its class.

Q: What is the average duration of relief expected after taking one tablet?

A: Clinical studies on efficacy generally track the sustained response to the drug up to 24 hours post-dose. This duration of monitoring is consistent with the drug's relatively prolonged action compared to some other acute migraine treatments.

Q: What are the signs that the medicine is actually working?

A: The medicine is intended to relieve migraine pain. Clinical trials evaluate the drug's effectiveness by measuring the proportion of participants who report a reduction in headache pain or achieve pain-free status two and four hours after administration.

Q: What are the signs of a serious, immediate allergic reaction to look out for?

A: Regulatory documents describe signs of a serious allergic reaction, which may include a rash, itching, trouble breathing, difficulty swallowing, or swelling of the hands, face, or mouth.

Q: Why does Нарамиг sometimes cause feelings of dizziness or drowsiness?

A: Official documents classify dizziness and drowsiness as commonly reported adverse reactions that involve the nervous system based on clinical trial data.

Q: Can this medication cause an increase in my blood pressure?

A: Official regulatory documents indicate the drug may be associated with an increase in blood pressure. On rare occasions, significant elevation in blood pressure, including a hypertensive crisis, has been reported.

Q: Can taking Нарамиг affect my heart rhythm?

A: Official regulatory information notes that the drug has the potential to cause heart rhythm changes, which may result in an irregular heartbeat. Rare but serious disturbances of cardiac rhythm have been reported in safety data.

Q: Can this drug interact with certain herbal supplements?

A: Official regulatory documents specifically note that the co-administration of this medicine with herbal preparations containing St John’s Wort may result in a higher frequency of undesirable effects.

Q: Is Нарамиг generally considered appropriate for men over 40 or women after menopause?

A: Official regulatory information states that men over 40 and postmenopausal women have cardiovascular risk factors that may necessitate evaluation for heart disease prior to the use of this medicine.

Q: Can people who are overweight still be prescribed Нарамиг?

A: Official regulatory warnings list obesity as a cardiovascular risk factor. Regulatory guidelines indicate that patients with cardiovascular risk factors should undergo a prior evaluation by a healthcare professional.

Q: What is the official information regarding the use of Нарамиг during pregnancy?

A: Official regulatory documentation states that the safety of the drug has not been established during pregnancy. Currently, there are no adequate and well-controlled studies in pregnant women to determine a drug-related risk, although animal studies have indicated potential developmental toxicity.

Q: Does the drug pass into breast milk?

A: It is currently unknown if the drug is excreted into human milk. Official regulatory guidance advises a waiting period of 24 hours after administration before resuming breastfeeding.

Q: Does Нарамиг contain lactose, and is that a concern?

A: The official list of inactive ingredients included in the formulation states that the tablet contains anhydrous lactose. This information is provided for patients with specific sensitivities.

Q: Is there any evidence for using Нарамиг to treat cluster headaches?

A: Official regulatory documents confirm that the safety and efficacy of this medicine have not been established for the management of cluster headaches.

Q: Does the manufacturer provide information on how to keep a headache diary?

A: Patient information provided by the manufacturer includes suggestions for keeping a headache diary to record headache frequency and drug use.

Q: Does the packaging of Нарамиг contain any sodium?

A: The official list of inactive ingredients included in the formulation states that the tablet contains croscarmellose sodium, a pharmaceutical excipient.

Q: Are there specific types of migraines, like basilar or hemiplegic, that are considered contraindications?

A: Official regulatory documents list that the use of this medicine is contraindicated in patients with a history of hemiplegic or basilar migraine.

How to Store and Dispose of Naramig

Official regulatory information outlines specific requirements for the storage and final disposal of Naramig (naratriptan) tablets to maintain product stability and safety.

Element	Regulatory Requirement
Storage Temperature	Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F).
Handling & Protection	Keep the medicine in its original, tightly closed container and keep from freezing. Store away from excess heat and moisture (not in the bathroom).
Child Safety	This medicine must be kept out of the sight and reach of children in a secure, safe location.
Disposal	Do not dispose of unused or expired tablets by flushing them down the toilet or throwing them into a drain. The product must be disposed of through a drug take-back program or according to local pharmaceutical waste regulations.

These mandated conditions ensure the integrity of the product until its expiration date. Any unused or expired medicine should be safely returned or discarded via regulated channels.